Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: oxidation specific epitopes antibodies - Calluna Pharma

Next Previous
Drug Profile

Research programme: oxidation specific epitopes antibodies - Calluna Pharma

Alternative Names: Research programme: OSE antibodies - Calluna Pharma

Latest Information Update: 28 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oxitope Pharma
  • Developer Calluna Pharma
  • Class Analgesics; Antibodies; Antifibrotics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Neuroprotectants
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Age-related macular degeneration; Aortic valve stenosis; Atherosclerosis; Bone disorders; Idiopathic pulmonary fibrosis; Ischaemic heart disorders; Mucocutaneous lymph node syndrome; Myocardial reperfusion injury; Neurodegenerative disorders; Non-alcoholic steatohepatitis; Pain; Respiration disorders; Rheumatoid arthritis

Most Recent Events

  • 28 Nov 2025 No recent reports of development identified for research development in Age-related-macular-degeneration in Netherlands (Parenteral)
  • 28 Nov 2025 No recent reports of development identified for research development in Aortic-valve-stenosis in Netherlands (Parenteral)
  • 28 Nov 2025 No recent reports of development identified for research development in Atherosclerosis in Netherlands (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top